Baseline characteristics of individual patients with HMA-naïve CMML in part 2B
| Patient no. . | Type . | Prior treatment . | Category . | LILRB4 in BM blasts, % . | LILRB4 copy number . | Blast in BM, % . | Molecular aberration . | Karyotype . | Splenomegaly . | Transfusion Dependence . | CPSS-Mol score . | MPN-SAF TSS . |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Proliferative | None | CMML-1 | 80.62% | 6457 | 1% | TET2, SRSF2, TP53, KRAS, NF1, JAK2, FAS, and SF3B1 | Normal | No | No | 1 | 28 |
| 2 | Dysplastic | None | CMML-1 | 52.90% | 4074 | 1% | ZRSR2 | Normal | No | Yes | 1 | 37 |
| 3 | Dysplastic | None | CMML-1 | 70.48% | 4898 | 5.8% | ASXL1 and CHEK2 | 46% loss of D20S108 at 20q12 | No | Yes | 4 | NA |
| 4 | Proliferative | None | CMML-1 | 61.99% | 4677 | 8% | TET2, ASXL1, DMT3A, KRAS, PTPN11, STAG2, and JAK2 | Normal | No | Yes | 4 | 21 |
| 5 | Dysplastic | None | CMML-1 | 6.15% | 1202 | 0.5% | ASXL1, RUNX1, PTPN11, EZH2 R583, and EZH2 c.2111-2A | Normal | No | Yes | 4 | 25 |
| 6 | Proliferative | None | CMML-1 | 1.74% | 708 | 0% | ASXL1, EZH2, RUNX1, and SDHA | Normal | No | No | 4 | 6 |
| 7 | Proliferative | Fedratinib | CMML-1 | 94.21% | 7762 | 5%-10% | ASXL1, and SRSF2 | Normal | No | No | 3 | NA |
| 8 | Proliferative | None | CMML-1 | 5.33 | 776 | 1% | ASXL1, ETV6, GATA2, and U2AF1 | Normal | No | Yes | 3 | 15 |
| 9 | Dysplastic | None | CMML-1 | 84.27% | 5495 | 2% | TET2, ZRSR2, SETBP1, KDM6A, BRCA1, and DNAH5 | Normal | No | no | 0 | 31 |
| 10 | Proliferative | None | CMML-2 | 66.52% | 3311 | 11% | TET2, SRSF2, ASXL1, RUNX1, and CREBBP | Normal | No | Yes | 6 | 15 |
| 11 | Proliferative | None | CMML-1 | 18.82% | 513 | 6% | ASXL1, RUNX1, KRAS, PHF6, and U2AF1 | Normal | No | No | 5 | 0 |
| 12 | Proliferative | Hydroxyurea | CMML-1 | 70.51% | 4169 | 1% | TET2, ASXL1, and CBL | Normal | No | No | 2 | 10 |
| 13 | Proliferative | Hydroxyurea | CMML-2 | 78.86% | 3548 | 12% | SETBP1, RUNX1, ASXL1, CBL, KRAS, TET2, and ZRSR2 | Normal | No | No | 5 | NA |
| 14 | Proliferative | None | CMML-1 | 80.36% | 6026 | 9% | ASXL1, NF1, SETBP1, SRSF2, and TET2 | t (3, 13), (p21, q12) | No | No | 5 | NA |
| 15 | Proliferative | None | CMML-1 | 9.11% | 2188 | 2.6% | TET2, ASXL1, CBL, and EZH2 | Normal | Yes | No | 2 | NA |
| 16 | Dysplastic | None | CMML-1 | 75.01% | 1479 | 6% | SRSF2, IDH2, CBR, and TP53 | Normal | No | No | 2 | 11 |
| 17 | Dysplastic | None | CMML-1 | NA | NA | 8% | ASXL1, CBL, and U2AF1 | Normal | No | No | 3 | NA |
| 18 | Dysplastic | None | CMML-1 | 23.03 | 646 | 2% | TET2, ASXL1, and CBL | Normal | No | Yes | 3 | 61 |
| 19 | Dysplastic | None | CMML-1 | 8.64% | 2754 | 3% | TET2, SF3B1, and JAK2 | Normal | No | No | 0 | 30 |
| 20 | Dysplastic | None | CMML-2 | 56.24 | 6166 | 18% | TP53 | Deletion 5q, 7q, 12p, monosomy 7 | No | no | NA | 53 |
| 21 | Proliferative | Hydroxyurea | CMML-2 | NA | NA | 3.4% | ASXL1, SETBP1, NRAS, and KIT | Abnormal | Yes | Yes | 7 | NA |
| Patient no. . | Type . | Prior treatment . | Category . | LILRB4 in BM blasts, % . | LILRB4 copy number . | Blast in BM, % . | Molecular aberration . | Karyotype . | Splenomegaly . | Transfusion Dependence . | CPSS-Mol score . | MPN-SAF TSS . |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Proliferative | None | CMML-1 | 80.62% | 6457 | 1% | TET2, SRSF2, TP53, KRAS, NF1, JAK2, FAS, and SF3B1 | Normal | No | No | 1 | 28 |
| 2 | Dysplastic | None | CMML-1 | 52.90% | 4074 | 1% | ZRSR2 | Normal | No | Yes | 1 | 37 |
| 3 | Dysplastic | None | CMML-1 | 70.48% | 4898 | 5.8% | ASXL1 and CHEK2 | 46% loss of D20S108 at 20q12 | No | Yes | 4 | NA |
| 4 | Proliferative | None | CMML-1 | 61.99% | 4677 | 8% | TET2, ASXL1, DMT3A, KRAS, PTPN11, STAG2, and JAK2 | Normal | No | Yes | 4 | 21 |
| 5 | Dysplastic | None | CMML-1 | 6.15% | 1202 | 0.5% | ASXL1, RUNX1, PTPN11, EZH2 R583, and EZH2 c.2111-2A | Normal | No | Yes | 4 | 25 |
| 6 | Proliferative | None | CMML-1 | 1.74% | 708 | 0% | ASXL1, EZH2, RUNX1, and SDHA | Normal | No | No | 4 | 6 |
| 7 | Proliferative | Fedratinib | CMML-1 | 94.21% | 7762 | 5%-10% | ASXL1, and SRSF2 | Normal | No | No | 3 | NA |
| 8 | Proliferative | None | CMML-1 | 5.33 | 776 | 1% | ASXL1, ETV6, GATA2, and U2AF1 | Normal | No | Yes | 3 | 15 |
| 9 | Dysplastic | None | CMML-1 | 84.27% | 5495 | 2% | TET2, ZRSR2, SETBP1, KDM6A, BRCA1, and DNAH5 | Normal | No | no | 0 | 31 |
| 10 | Proliferative | None | CMML-2 | 66.52% | 3311 | 11% | TET2, SRSF2, ASXL1, RUNX1, and CREBBP | Normal | No | Yes | 6 | 15 |
| 11 | Proliferative | None | CMML-1 | 18.82% | 513 | 6% | ASXL1, RUNX1, KRAS, PHF6, and U2AF1 | Normal | No | No | 5 | 0 |
| 12 | Proliferative | Hydroxyurea | CMML-1 | 70.51% | 4169 | 1% | TET2, ASXL1, and CBL | Normal | No | No | 2 | 10 |
| 13 | Proliferative | Hydroxyurea | CMML-2 | 78.86% | 3548 | 12% | SETBP1, RUNX1, ASXL1, CBL, KRAS, TET2, and ZRSR2 | Normal | No | No | 5 | NA |
| 14 | Proliferative | None | CMML-1 | 80.36% | 6026 | 9% | ASXL1, NF1, SETBP1, SRSF2, and TET2 | t (3, 13), (p21, q12) | No | No | 5 | NA |
| 15 | Proliferative | None | CMML-1 | 9.11% | 2188 | 2.6% | TET2, ASXL1, CBL, and EZH2 | Normal | Yes | No | 2 | NA |
| 16 | Dysplastic | None | CMML-1 | 75.01% | 1479 | 6% | SRSF2, IDH2, CBR, and TP53 | Normal | No | No | 2 | 11 |
| 17 | Dysplastic | None | CMML-1 | NA | NA | 8% | ASXL1, CBL, and U2AF1 | Normal | No | No | 3 | NA |
| 18 | Dysplastic | None | CMML-1 | 23.03 | 646 | 2% | TET2, ASXL1, and CBL | Normal | No | Yes | 3 | 61 |
| 19 | Dysplastic | None | CMML-1 | 8.64% | 2754 | 3% | TET2, SF3B1, and JAK2 | Normal | No | No | 0 | 30 |
| 20 | Dysplastic | None | CMML-2 | 56.24 | 6166 | 18% | TP53 | Deletion 5q, 7q, 12p, monosomy 7 | No | no | NA | 53 |
| 21 | Proliferative | Hydroxyurea | CMML-2 | NA | NA | 3.4% | ASXL1, SETBP1, NRAS, and KIT | Abnormal | Yes | Yes | 7 | NA |
Included were 21 patients from safety analysis set.
NA, not available.